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antiatherogenic function of HDL in experimental studies. However, it remains unclear whether cholesterol-overloaded
HDL particle is involved in the development of atherosclerosis in humans.
OBJECTIVES The objective of this study was to explore whether cholesterol-overloaded HDL particles are associated
with the progression of carotid atherosclerosis in a cardiovascular disease–free population.
METHODS Baseline HDL particle number was measured using nuclear magnetic resonance spectroscopy in 930 par-
ticipants ages 45 to 74 years in a community-based cohort study. An estimate of cholesterol molecules per HDL particle
(HDL-C/P ratio) was calculated as the ratio of HDL cholesterol to HDL particles. HDL-C/P ratio was categorized as
<41.0 (lowest), 41.0 to 46.9, 47.0 to 52.9, and $53.0 (highest) using a ﬁxed increment method. Modiﬁed Poisson
regression was used to assess the association between HDL-C/P ratio and 5-year progression of carotid atherosclerosis as
indicated by progression of carotid plaques and change in total plaque area (TPA).
RESULTS Mean baseline HDL-C/P ratio was 46.4  9.3 (range 23.8 to 86.9). Baseline HDL-C/P ratio was signiﬁcantly
associated with 5-year progression of carotid atherosclerosis. Participants with the highest HDL-C/P ratio had 1.56-fold
(95% conﬁdence interval: 1.14 to 2.13; p ¼ 0.006) increased progression compared with those with the lowest level.
Among participants without baseline plaque, TPA in re-examination was larger by 9.4 mm2 in the subgroup with the
highest level when compared with the lowest level.
CONCLUSIONS Our ﬁndings suggest that cholesterol-overloaded HDL particles are independently associated with the
progression of carotid atherosclerosis. This may explain why in recent trials raising HDL cholesterol was not beneﬁcial.
This study strongly suggests that the combination of cholesterol content and particle number determines the anti-
atherogenic function of HDLs, rather than either parameter alone. (J Am Coll Cardiol 2015;65:355–63) © 2015 by the
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ABBR EV I A T I ON S
AND ACRONYMS
ASCVD = atherosclerotic
cardiovascular disease
BMI = body mass index
BP = blood pressure
CETP = cholesteryl ester
transfer protein
CI = conﬁdence interval
CVD = cardiovascular disease
FBG = fasting blood glucose
HDL-C = high-density
lipoprotein cholesterol
HDL-C/P ratio = the ratio of
HDL-C to HDL-P number
HDL-P = high-density
lipoprotein particles
hs-CRP = high-sensitivity
C-reactive protein
LDL-P = low-density
lipoprotein particle
NMR = nuclear
magnetic resonance
RR = relative risk
TPA = total plaque area of
maximum plaques
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356A lthough observational studies havesuggested high-density lipoproteincholesterol (HDL-C) as an indepen-
dent inverse predictor for atherosclerotic
cardiovascular diseases (ASCVDs) (1), several
large randomized controlled trials in which
plasma HDL-C was raised failed to show
beneﬁt for cardiovascular disease (CVD)
events or progression of atherosclerosis (2,3).
Recent updated American Heart Association/
American College of Cardiology and European
Society of Cardiology guidelines do not
recommend raising HDL-C as a means to pre-
vent ASCVD (4).SEE PAGE 364However, debate regarding the value of
HDL-C in CVD prevention continues (5–7). A
core question is whether HDL-C fully repre-
sents cholesterol reverse transport, an un-
derpinning of the antiatherogenic function of
HDL. Experimental studies point out that the
concentration of HDL particles (HDL-P),
rather than the cholesterol carried by these
particles, might be the appropriate parameter
for assessing the function of HDL (8,9).Several observational studies have proven HDL-P
number to be more strongly associated with CVD
risk than HDL-C (10,11). Indeed, cholesteryl ester
transfer protein (CETP) inhibitor or niacin was found
in recent randomized controlled trials to have little
effect on HDL-P number. This was true even if HDL-C
was substantially increased, thus resulting in
increased cholesterol-overloaded HDL-P (5,12). There
is evidence that cholesterol-overloaded HDL-P may
be harmful because experimental studies observed
that cholesterol-overloaded HDL-P not only exerted a
negative impact on the efﬂux potential of cholesterol
from extrahepatic cells (7,13) but also reduced hepatic
selective uptake of cholesterol mediated by scavenger
receptor class B member 1 (SR-BI) (14–16). However,
it remains unclear whether cholesterol-overloaded
HDL-P is involved in the development of atheroscle-
rosis in humans.
In this study, we calculated the ratio of HDL-C to
HDL-P number (HDL-C/P ratio) to estimate the
cholesterol content per HDL-P in a CVD-free popula-
tion. Speciﬁcally, a high HDL-C/P ratio indicates
cholesterol-overloaded HDL-P. We therefore tested
the hypothesis that cholesterol-overloaded HDL-P
may be associated with the progression of carotid
atherosclerosis in asymptomatic individuals from a
community-based cohort study of the Chinese Multi-
provincial Cohort Study (CMCS)-Beijing Project.MATERIALS AND METHODS
STUDY PARTICIPANTS. Study participants were
recruited from the CMCS-Beijing Project, which is a
generally healthy population-based study (17). Of
1,982 participants originally enrolled from a commu-
nity in Beijing in 1992, a total of 1,324 participants
ages 45 to 74 years completed examinations on
demographic characteristics, measurements of tradi-
tional risk factors, and carotid ultrasound from
September to November 2002. After excluding par-
ticipants with established CVD (n ¼ 68), unavailable
blood samples (n ¼ 7), and incomplete data (n ¼ 14) at
baseline, 1,235 participants were followed up for the
occurrence of CVD and then invited to repeat exam-
inations for risk factors and carotid ultrasound in
2007. Sixty-two participants were lost to follow-up, 15
died, and 228 did not participate at re-examinations.
Thus, 930 (418 men and 512 women) participants
with complete data from 2 examinations were eligible
for ﬁnal analysis.
All participants gave written informed consent,
and this study was approved by the ethics committee
of Beijing An Zhen Hospital, Capital Medical Uni-
versity, and was performed in accordance with the
Declaration of Helsinki.
RISK FACTOR SURVEY. This study complied with the
protocol of the World Health Organization-MONICA
(Monitoring of Trends and Determinants in Cardio-
vascular Disease). Demographic characteristics and
personal medical history were collected by a standard
questionnaire. Anthropometric measurements and
blood pressure (BP) levels were recorded during
physical examination. Body mass index (BMI) was
calculated as weight in kilograms divided by height
squared in meters. The survey method and deﬁnition
of risk factors, including hypertension, diabetes, and
current smoking, were previously described (17).
LABORATORY ASSAYS. Venous blood samples were
drawn from the antecubital vein and collected in
lavender-top tube(s) containing EDTA anticoagulant
in the morning after fasting at least 8 h. Lipid proﬁles,
fasting blood glucose (FBG), and high-sensitivity
C-reactive protein (hs-CRP) were measured on fresh
samples at the same day of collection in 2002 ac-
cording to previous reports (17). HDL-C levels were
measured by homogeneous assays (Daiichi, Tokyo,
Japan). The remaining samples were aliquoted and
stored at 80C. Plasma lipoprotein particle numbers
were measured in 2013 using a commercially available
nuclear magnetic resonance (NMR) spectroscopy
assay at LipoScience (Raleigh, North Carolina).
Brieﬂy, samples for lipoprotein particle analysis using
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357proton NMR spectroscopy were thawed, separated
into 500-ml aliquots, refrozen, and shipped on dry ice
to LipoScience. This method uses the characteristic
signals broadcast by lipoprotein subfractions of
different size as the basis for quantiﬁcation.
CAROTID ATHEROSCLEROSIS MEASUREMENTS. Carotid
atherosclerosis was measured using high-resolution
B-mode ultrasound. The method and the measure-
ment validation are detailed in the Online Appendix.
Brieﬂy, the presence of plaque was deﬁned as an
intima-media thickness $1.5 mm, or a focal structure
that encroached into the arterial lumen $0.5 mm,
or $50% of the surrounding intima-media thickness
(18). Progression of carotid plaque was deﬁned as the
appearance of at least 1 plaque at re-examination in a
previously plaque-free arterial segment. Addition-
ally, Vascular Research Tools 6 carotid analyzer
(Medical Imaging Applications, Coralville, Iowa) was
used to measure the total plaque area of maximum
plaques (TPA), which can evaluate the progression
of carotid atherosclerosis among participants with
new-onset plaque who had no baseline plaque.
STUDY POWER ESTIMATION. No studies have yet
investigated the association between baseline HDL-P
number and carotid atherosclerosis progression.
Based on a recent meta-analysis (19), risk estimates
between baseline HDL-P number and CVD risk ranged
from 0.62 to 0.82. In this study, the 5-year progres-
sion rate of carotid plaque was 52.9%. The estimated
sample size was 208 if risk estimate was 0.62, and 904
if risk estimate was 0.82, assuming an alpha (proba-
bility of type I error) of 0.05 and delta (admissible
error) of 0.10. The actual sample size of 930 in this
study enabled us to have sufﬁcient statistical power.
STATISTICAL ANALYSIS. Continuous variables, ex-
pressed either as mean  SD in case of normally
distributed variables or as median (interquartile
ranges), were compared using unpaired Student t test
or Mann-Whitney U test or 1-way analysis of variance,
where appropriate. Categorical variables, expressed as
number (percent), were compared using the chi-square
test. Correlations were estimated using Spearman rank
method while adjusting for age and sex.
We calculated proportions within subgroups of
HDL-C level among subgroups of HDL-P numbers.
HDL-C and HDL-P number were categorized using the
ﬁxed-increment method. For HDL-C, the cutoff point
of the lowest level was deﬁned by the criterion of
low HDL-C (<1.04 mmol/l). A ﬁxed increment of
0.25 mmol/l was then used and study participants
classiﬁed into 3 groups (<1.04, 1.04 to 1.29,
$1.30 mmol/l). For HDL-P number, the cutoff point of
the lowest level was set at 28.0, which is the cutoffpoint of the lowest tertile. A ﬁxed increment of
4 mmol/lwas used and study participants classiﬁed into
3 groups (<28.0, 28.0 to 31.9, $32.0 mmol/l). An esti-
mate of cholesterol molecules per HDL-P (HDL-C/P
ratio) can be obtained by calculating the ratio of HDL-C
to HDL-P numbers. The units of HDL-C were trans-
formed to mmol/l from the original mmol/l unit when
calculating the HDL-C/P ratio. HDL-C/P ratio was
categorized into 4 groups (<41.0, 41.0 to 46.9, 47.0
to 52.9, $53.0). The cutoff point of the lowest level
was set at 41.0, which is the cutoff point of the lowest
quartile. The increment value was 6.
Relative risk (RR) for 5-year progression of carotid
plaque within combined subgroups of HDL-C, and
HDL-P number was calculated using a modiﬁed Pois-
son regression model while adjusting for known CVD
risk factors (age, sex, BMI, systolic BP, diabetes, cur-
rent smoking, and triglycerides), low-density lipopro-
tein particle (LDL-P) numbers, HDL-P size, and 5-year
changes in systolic BP, total cholesterol, HDL-C, and
FBG. Risk estimates were calculated in each combined
subgroup using the subgroupwith both highest level of
HDL-C and HDL-P number as a reference.
Furthermore, associations between HDL-C/P ratio
and the risk for 5-year progression of carotid plaque
were analyzed to evaluate the impact of the cholesterol
amount per HDL particle after adjusting for HDL-C and
HDL-P number. Risk estimates were then calculated
for participants in each subgroup of HDL-C/P ratio,
HDL-C and HDL-P number using the lowest category as
references, respectively. Additionally, association
between HDL-C/P ratio and changes in TPA was
analyzed using multiple linear regression models
among those with new-onset carotid plaque who had
no baseline plaque in all segments of carotid artery.
Additional adjustment was performed for baseline
LDL-C, hs-CRP levels, and lipid-lowering medication.
To test whether missing data would yield poten-
tial bias, comparisons were performed between 930
participants who were eligible in ﬁnal analyses, lost
to follow-up, and unavailable for re-examinations,
and no signiﬁcant differences were observed (Online
Table 1).
Statistical analyses were performed using SAS
software (version 9.3, SAS Institute, Cary, North
Carolina). Values of p < 0.05 were considered statis-
tically signiﬁcant. Sample size estimation was calcu-
lated using PASS software (version 8.0, NCSS,
Kaysville, Utah).
RESULTS
BASELINE CHARACTERISTICS OF THE STUDY
PARTICIPANTS. A total of 930 participants (mean
TABLE 1 Baseline Ch
Age, yrs
Systolic blood pressure
mm Hg
Diastolic blood pressur
mm Hg
Body mass index, kg/m
Fasting blood glucose,
mmol/l
Hs-CRP, mg/l
Obesity
Current smoking
Hypertension
Diabetes
Lipid-lowering treatme
Prevalence of carotid p
Baseline maximal IMT,
Standard chemical lipid
Total cholesterol, mm
LDL cholesterol, mm
HDL cholesterol, mm
Triglycerides, mmol/
NMR lipoprotein partic
number
HDL particle number
mmol/l
Total
Large
Medium
Small
LDL particle number
nmol/l
Total
Large
Small
NMR lipoprotein partic
size, nm
HDL
LDL
Values are mean  SD, me
was deﬁned as smoking
pressure <140 mm Hg sy
mellitus was deﬁned by fas
HDL ¼ high-density lipo
LDL ¼ low-density lipopro
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358age, 59.6  7.8 years; 55.1% women) were enrolled,
and their baseline characteristics are shown in Table 1.
Mean baseline HDL-C level and HDL-P number were
1.40  0.31 (range 0.62 to 2.93) mmol/l and 30.3  4.6
(range 18.3 to 53.6) mmol/l, respectively. The preva-
lence of carotid plaque was 19.5% at baseline.
HDL-C, HDL-P, AND HDL-C/P RATIO. HDL-C and
HDL-P number were positively correlated (partial
r ¼ 0.378) (Online Table 2). HDL-C and HDL-P number
were categorized and combined into 9 groups
(Figure 1). Participants in the highest category of
HDL-P number included 95.0% of participants witharacteristics of the Study Participants
Total (N ¼ 930) Men (n ¼ 418) Women (n ¼ 512)
59.6  7.8 61.1  7.4 58.3  8.0
, 129.6  18.2 132.3  17.6 127.5  18.5
e, 80.8  10.1 83.2  10.2 78.8  9.5
2 25.0  3.3 25.1  2.9 24.9  3.5
4.90  0.99 4.85  1.04 4.95  0.93
0.84 (0.38-1.77) 0.80 (0.40-1.63) 0.88 (0.37-1.92)
161 (17.3) 59 (14.1) 102 (19.9)
89 (9.6) 88 (21.1) 1 (0.2)
445 (47.8) 227 (54.3) 218 (42.6)
99 (10.6) 50 (12.0) 49 (9.6)
nt 110 (11.8) 44 (10.5) 66 (12.9)
laque 181 (19.5) 100 (23.9) 81 (15.8)
mm 0.90 (0.70-1.20) 1.00 (0.80-1.40) 0.90 (0.70-1.10)
s
ol/l 5.57  1.02 5.39  0.96 5.72  1.04
ol/l 3.35  0.83 3.30  0.81 3.40  0.85
ol/l 1.40  0.31 1.29  0.26 1.78  0.32
l 1.29 (0.94-1.86) 1.27 (0.96-1.83) 1.29 (0.92-1.88)
le
,
30.3  4.6 28.7  4.1 31.6  4.7
4.5 (3.1-6.4) 3.5 (2.4-5.1) 5.3 (3.9-7.0)
5.3 (3.5-7.6) 4.9 (3.3-6.6) 6.0 (3.8-8.2)
19.6 (17.3-21.7) 19.6 (17.5-21.7) 19.7 (17.0-22.0)
,
1,088.0  272.2 1,075.4  262.8 1,098.1  278.7
253.5 (129.7-369.0) 258.0 (126.0-371.0) 249.0 (132.0-367.0)
585.5 (411.7-807.0) 591.0 (438.0-795.0) 576.0 (394.0-818.0)
le
9.1  0.4 8.9  0.4 9.2  0.4
20.6  0.6 20.5  0.6 20.6  0.6
dian (interquartile range), or n (%). Obesity was deﬁned by BMI $28 kg/m2. Smoking
1 or more cigarettes per day for 3 months. Hypertension was deﬁned as blood
stolic, <90 mm Hg diastolic, and/or current antihypertensive treatment. Diabetes
ting plasma glucose$7.0 mmol/l or currently on glucose-lowering medical treatment.
protein; Hs-CRP ¼ high-sensitivity C-reactive protein; IMT ¼ intima-media thickness;
tein; NMR ¼ nuclear magnetic resonance.HDL-C level $1.04 mmol/l, and 47.0% of participants
with HDL-C level $1.55 mmol/l. However, partici-
pants with the lowest category of HDL-P num-
ber included 80.9% of participants with HDL-C
level $1.04 mmol/l and 16.3% of participants with
HDL-C level $1.55 mmol/l. Moreover, the levels of
large HDL-P number (median [interquartile range]:
8.6 [6.9 to 9.4] mmol/l) and HDL-P size (9.9  0.3 nm)
were the highest in the subgroup of the lowest HDL-P
number and the highest HDL-C level.
An estimation of cholesterol molecules per HDL-P
(HDL-C/P ratio) was calculated. Mean HDL-C/P ratio
was 46.4  9.3 (range 23.8 to 86.9) (Online Figure 1).
HDL-C/P ratio was positively correlated with HDL-C
(partial r ¼ 0.755), but negatively correlated with
HDL-P number (partial r ¼ 0.300) (Online Table 2).
ASSOCIATION BETWEEN HDL-C/P RATIO AND THE
PROGRESSION OF CAROTID ATHEROSCLEROSIS. Of
930 participants, 52.9% developed new-onset plaque
during 5-year follow-up. The RRs for progression
within combined subgroups of HDL-C and HDL-P
number were calculated (Central Illustration). In any
category of the HDL-C subgroup, the progression risk
increased with a decrease in HDL-P numbers, despite
being signiﬁcant only at the highest level of HDL-C. By
contrast, within HDL-P subgroups, HDL-C was gener-
ally not inversely associated with the progression risk.
At the highest level of HDL-P number, the risk
increased with a decrease in HDL-C level. However, at
the lowest level of HDL-P number, the risk increased
with an increase in HDL-C level. Speciﬁcally, partici-
pants who simultaneously had both the highest HDL-C
and the lowest HDL-P number had higher progression
risk than those who simultaneously had both the
highest HDL-C and highest HDL-P number (RR: 1.55,
95% conﬁdence interval [CI]: 1.05 to 1.92; p ¼ 0.006).
Although the combined subgroup of HDL-C and HDL-P
number qualitatively reﬂected the unmatched phe-
nomena of HDL-C and HDL-P number and possible
association with atherosclerosis, it was not a quanti-
tative indicator for the mean level of cholesterol per
HDL particle for each study participants.
We further explored the association of cholesterol
molecules per particle (indicated by HDL-C/P ratio)
with 5-year progression of carotid plaque. Modiﬁed
Poisson regression analysis showed that the RR for
progression at the highest level of HDL-C/P ratio was
1.56 (95% CI: 1.14 to 2.13; p ¼ 0.006) (Table 2)
compared with the lowest level while adjusting for
HDL-C and HDL-P number. The trend test indicated
that with increasing HDL-C/P ratio, the progression
risk was signiﬁcantly increased (p for trend ¼ 0.006).
Additionally, baseline HDL-C was signiﬁcantly and
FIGURE 1 Percentage of HDL-C Subgroups Among Subgroups of HDL-P Numbers
HDL-C <1.04 mmol/L
≥32.0 5.0(17/342)
4.9
(14/283)
19.1
(58/304)
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(124/304)
40.4
(115/283)
54.2
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HDL-C level was categorized as <1.04, 1.04 to 1.29, $1.30 mmol/l, and HDL-P number
as <28.0, 28.0 to 31.9, $32.0 mmol/l. Results are presented as percentages (subgroup
number/total number). HDL ¼ high-density lipoprotein; HDL-C ¼ high-density lipoprotein
cholesterol; HDL-P ¼ high-density lipoprotein particle.
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359negatively associated with 5-year progression of ca-
rotid plaque after adjusting for HDL-C/P ratio. RRs for
carotid plaque progression at the highest level of
HDL-C compared with the lowest level was 0.74 (95%
CI: 0.61 to 0.94; p ¼ 0.03).
Of 749 participants who had no baseline plaque in
all segments of carotid artery, 48.7% had incidence of
new-onset plaque. We investigated the association
between baseline HDL-C/P ratio and incidence of
new-onset plaque, and found the same relationship
(Table 2).
Among participants without baseline plaque, mean
TPA was 27.0  20.4 and a median 21.6 mm2 in
re-examination. Online Table 3 showed multiple
adjusted TPA according to the subgroups of baseline
HDL measures. Baseline HDL-C/P ratio was signiﬁ-
cantly associated with the TPA. In participants
without baseline plaque, the TPA in re-examination
was larger by 9.4 mm2 in the subgroup with the
highest level of HDL-C/P ratio than the lowest
level. However, baseline HDL-C was signiﬁcantly and
negatively associated with the TPA, even after
adjusting for HDL-C/P ratio. In participants without
baseline plaque, the TPA in re-examination was larger
by 7.8 mm2 in the subgroup with the lowest level of
HDL-C than the highest level.
Further adjustment for baseline LDL-C, hs-CRP
levels, and lipid-lowering medication had no effect
on risk estimates for HDL-C/P ratio (Online Table 4).
DISCUSSION
In this community-based cohort study, the cholesterol
content of HDL-P was highly variable, suggesting the
substantial existence of cholesterol-overloaded parti-
cles among asymptomatic individuals. Moreover
and importantly, we reported for the ﬁrst time
that cholesterol-overloaded HDL-P was associated
with increased progression of carotid atherosclerosis
(Central Illustration).
SUBSTANTIAL EXISTENCE OF CHOLESTEROL-
OVERLOADED HDL PARTICLES. In this study, we
calculated the HDL-C/P ratio to assess the content of
cholesterol per particles, and found 3.78-fold varia-
tion among asymptomatic individuals. One par-
ticipant may have cholesterol-overloaded HDL-P,
whereas another may have cholesterol-poor HDL-P.
From a biochemical perspective, HDL-C is merely an
index reﬂecting how much cholesterol is carried by
the pool of HDL-P in the blood. However, the terms
HDL-C and HDL-P are not synonymous, as illus-
trated in our study, and there are substantial inter-
individual variations. The reasons are understood
mechanistically, either naturally or as a result ofHDL-raising therapy. The HDLs in human plasma vary
in quantitative and qualitative content of lipids.
Subjects with genetic CETP deﬁciency exhibited high
levels of large cholesterol-enriched HDL-P (20).
Moreover, interventions that raise HDL-C levels,
including CETP inhibitors and niacin, had little
effect on HDL function (21), and tend to increase
cholesterol-overloaded particles (12). However, the
evidence linking functions to this speciﬁc form of
HDLs in humans is sparse.
CHOLESTEROL-OVERLOADED HDL PARTICLES AND
ATHEROSCLEROSIS. Our ﬁndings suggested that
very high levels of cholesterol-overloaded HDL-P are
independently associated with the increased risk of
carotid atherosclerosis in asymptomatic individuals.
It is possible that HDL-P may be dysfunctional despite
high levels of HDL-C. Previous data in humans have
shown that low levels of the small, denser HDL
(HDL3) subfraction carried higher risk than the
large, less dense HDL (HDL2) subfraction in primary
prevention (22) and secondary prevention (23). This
could be in accordance with our ﬁndings, because
these individuals would be overall shifted toward
a more cholesterol-loaded state, with potentially
less capacity for cholesterol efﬂux (24). Moreover,
other observational studies, consistent with our
ﬁndings, have suggested that high HDL-C levels or
larger size of HDL-P, when not accompanied by a
correspondingly high level of HDL-P number or
CENTRAL ILLUSTRATION Cholesterol-Overloaded HDL-P and Atherosclerosis: Relative Risk for Carotid Plaque
Progression Among Subgroups Deﬁned by Levels of HDL-P Number and HDL-C
Combined Subgroup of HDL-C and HDL-P Number
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Qi, Y. et al. J Am Coll Cardiol. 2015; 65(4):355–63.
Data were compared between participants with high HDL-P and high HDL-C and the others, after adjusting for age, sex, smoking, diabetes,
body mass index, systolic blood pressure (SBP), low-density lipoprotein particle, triglyceride, HDL-P size, and 5-year changes in SBP, total
cholesterol, HDL-C, and fasting blood glucose. HDL-C level was categorized as <1.04 (low), 1.04 to 1.29, $1.30 (high) mmol/l, and HDL-P
number as <28.0 (low), 28.0 to 31.9, $32.0 (high) mmol/l. **Risk estimates were calculated in each subgroup using the subgroup with both
highest level of HDL-C and HDL-P number as a reference. p < 0.01. HDL-C ¼ high-density lipoprotein cholesterol; HDL-P ¼ high-density
lipoprotein particle.
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360apolipoprotein A-I (a rough measure of HDL-P), may
be signiﬁcantly associated with increased rather than
decreased CVD risk (25). This epidemiological obser-
vation paralleled the ﬁndings of some experimental
studies, and several potential biological mechanisms
explain how this type of HDL can become pro-
atherogenic. First, enrichment of HDL-P in choles-
terol leads to impairments in HDL reverse cholesterol
transport capacity (7,13). Moreover, exchange of
cholesterol esters between HDL and peripheral cells is
known to be bidirectional, in part mediated by SR-BI
(26,27). Thus, cholesterol-overloaded HDL-P may at
some point become cholesterol donors instead of ac-
ceptors. Additionally, cholesterol-overloaded HDL-P
have also been shown to be ineffective in SR-
BI–mediated cholesterol selective uptake in the liver,
and ﬁltration and clearance in the kidney (14–16).Second, although it is acknowledged that the anti-
inﬂammatory capacity of HDL contributes to its
antiatherogenic potency, HDL may become proin-
ﬂammatory when in the large and cholesterol-
enriched form (28). Third, large, less dense HDL
impairs protection from oxidation (29). The accumu-
lation of oxidized HDL results in impairments of
cholesterol efﬂux (30), and interferes with SR-BI–
mediated cholesterol selective transfer to hepatocytes
(31). Conceivably, a very high level of cholesterol con-
tent per HDL-P may induce a proatherogenic lipopro-
tein proﬁle via these 3mechanisms. However, whether
these mechanisms have physiological relevance in
humans requires further investigation.
This study has shown that baseline HDL-C was
signiﬁcantly and negatively associated with carotid
atherosclerosis progression, independent of HDL-C/P
TABLE 2 Modiﬁed Poisson Regression Analysis of the Associations Between HDL-C/P
Ratio, HDL-P Number, HDL-C, and the Progression of Carotid Atherosclerosis
Progression of
Carotid Plaque
Incidence of New-Onset
Carotid Plaque
RR (95% CI) p Value* RR (95% CI) p Value*
HDL-C/P ratio
<41.0 Ref Ref
41.0–46.9 1.20 (1.00-1.44) 0.05 1.17 (0.93-1.48) 0.17
47.0–52.9 1.32 (1.04-1.67) 0.02 1.23 (0.91-1.67) 0.06
$53.0 1.56 (1.14-2.13) 0.006 1.47 (1.00-2.16) 0.04
HDL-P number, mmol/l
<28.0 Ref Ref
28.0–32.9 1.03 (0.88-1.22) 0.70 0.94 (0.77-1.15) 0.55
$33.0 0.95 (0.77-1.18) 0.64 0.88 (0.68-1.14) 0.33
HDL-C, mmol/l
<1.04 Ref Ref
1.04–1.29 0.87 (0.74-1.03) 0.11 0.93 (0.75-1.16) 0.55
$1.30 0.74 (0.61-0.94) 0.03 0.83 (0.66-0.99) 0.05
Age, 5-yr 1.17 (1.11-1.22) <0.001 1.15 (1.09-1.21) <0.001
SBP, 5 mm Hg 1.04 (1.02-1.06) <0.001 1.05 (1.02-1.08) <0.001
LDL-P, 200 nmol/l 1.10 (1.04-1.15) 0.001 1.11 (1.04-1.19) 0.002
Smoking 1.24 (1.03-1.50) 0.03 1.34 (1.06-1.70) 0.02
Diabetes 1.32 (1.09-1.60) 0.004 1.38 (1.11-1.72) 0.004
5-yr SBP change, 5 mm Hg 1.03 (1.01-1.05) 0.006 1.04 (1.01-1.07) 0.003
*All substantial models are additionally adjusted for sex, body mass index (1 kg/m2), triglyceride, HDL-P size, and
changes in total cholesterol, HDL-C, and fasting blood glucose. Smoking was deﬁned as smoking 1 or more
cigarettes per day for more than 3 months. Diabetes was deﬁned by fasting plasma glucose $7.0 mmol/l or
currently on glucose-lowering medical treatment.
CI ¼ conﬁdence interval; HDL-C ¼ high-density lipoprotein cholesterol; HDL-C/P ratio ¼ the ratio of HDL-C to
HDL-P number (giving the content of cholesterol per HDL-P); HDL-P¼ high-density lipoprotein particle; LDL-P¼
low-density lipoprotein particle; RR ¼ relative risk; SBP ¼ systolic blood pressure.
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361ratio. This suggests that HDL-C indicates the cargo of
HDL particles and may, therefore, reﬂect the potential
for reverse cholesterol transport if the undesirable ef-
fects of cholesterol-overloaded HDL-P can be
removed. This association can account for why recent
clinical trials using CETP inhibitors that increase
the level of HDL-C have failed to demonstrate any
beneﬁt for atherosclerosis. Additionally, although
baseline HDL-P number was nonsigniﬁcantly associ-
ated with carotid plaque progression after adjusting
for HDL-C/P ratio in this study, stratiﬁed analyses
showed that at any given category of HDL-C level, this
progression risk increased with decreasing HDL-P
numbers. These ﬁndings suggest that HDL-P numbers
may still be a proper metric of HDL, and provide more
information beyond HDL-C. Indeed, ex vivo studies
showed that a greater HDL-P number may indicate
high reverse cholesterol transport capacity indepen-
dent of HDL-C, and increasing binding to SR-BI and
high efﬁciency of subsequent lipid transfer (8,9,27,32).
STUDY LIMITATIONS. The present study is the ﬁrst
large-scale study conducted in a general Chinese
population to assess the cholesterol content per
HDL-P, calculated by the ratio of HDL-C to HDL-P
number, and we found substantial existence of
cholesterol-overloaded HDL-P in asymptomatic in-
dividuals from a community-based cohort study.
Moreover, we investigated the relation between
cholesterol-overloaded HDL-P and carotid athero-
sclerosis, and found an independent positive associa-
tion. Despite these clear strengths, our study has
several possible limitations. First, HDL-C quantiﬁed in
the clinical laboratory came from the various HDL
subclasses. It is unknown which HDL functions are
clinically important, and whether some functions are
more antiatherogenic than others. However, we used
the ratio of HDL-C to HDL-P number to assess the
cholesterol content per HDL-P, and found an inde-
pendent association for atherosclerosis after adjust-
ing for HDL-P size. Although our ﬁndings suggest
that the amount of cholesterol molecules per HDL-P
exerts an important effects on atherosclerosis, the
composition of cholesterol molecules carried by
HDL-P, such as the differences between HDL sub-
populations in the abundance of cholesteryl ester and
free cholesterol (7), is also a crucial research frontier.
This needs to be studied further, and may provide
important insights into the multifarious anti-
atherogenic effects of HDL. Second, the present
results were observational, which precluded any
causal inference. Although we adjusted for many
confounding factors, residual confounding by im-
perfectly measured or unmeasured confounders
cannot be excluded, such as dietary factors and thetypes of lipid-lowering medications. However, this is
a common limitation of a nonrandomized study,
mandating the need for further studies. Third, the
sample size, although reasonably large, reﬂects only a
proportion of the original cohort. To ascertain
whether the missing data would yield a potential
bias, we compared the baseline characteristics among
study participants who were eligible, lost to follow-
up, and unavailable for re-examination, and we
found no signiﬁcant differences. Nevertheless, this
ﬁnding still highlights the need for extensive repli-
cation and clinical validation of our results in larger
studies. Finally, the fact that our study participants
were Chinese may limit the generalizability of our
ﬁndings, necessitating further conﬁrmation in other
ethnic populations.
CONCLUSIONS
Our ﬁndings suggest that there are substantial varia-
tions in cholesterol content per HDL-P, and individuals
may have cholesterol-overloaded HDL-P. Moreover,
cholesterol-overloaded HDL-P may be a strong pre-
dictor of carotid atherosclerosis risk, implying that in
cases of high levels of cholesterol-overloaded HDL-P,
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Cholesterol-overload HDL particles may predict
atherosclerotic risk despite high HDL-C levels and
might explain why high plasma HDL-C levels have
failed to avoid ischemic events in some clinical
trials.
TRANSLATIONAL OUTLOOK: Consideration of
the combination of cholesterol content and HDL
particle number, rather than either parameter
alone, may help direct future efforts to reduce
atherogenesis by lowering the cholesterol content
of HDL particles.
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362an individual may be more prone to atherosclerosis
risk despite high HDL-C levels. The cholesterol con-
tent and particle number of HDL codetermined the
antiatherogenic potency. These ﬁndings may help
direct future efforts to reduce ASCVD beyond the
isolated increase in cholesterol content of HDLs, and
the focus of future intervention studies should be, not
only on raising HDL-C levels, but also on lowering
cholesterol-overloaded HDL-P.
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